Bone Biologics (BBLG) vs Biodexa Pharmaceuticals American Depositary Shs (BDRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bone Biologics is the larger company by market cap ($1.3 million vs $1.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBLG | BDRX |
|---|---|---|
| Share price | $0.4691 | $0.5237 |
| Market cap | $1.29M | $1.15M |
| 1-day change | -3.77% | -7.11% |
| P/E ratio (TTM) | — | 0.01 |
| EPS (TTM) | $-1.37 | $63.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.76 | $52.05 |
| 52-week low | $0.428 | $0.511 |
| Distance from 52-week high | -83.00% | -98.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +2500.72% | +1601.36% |
| Average volume | 378.20K | 3.72M |
| Shares outstanding | 2.76M | 2.20M |
| Employees | 2 | 11 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bone Biologics
BBLG stock →Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
Healthcare · Biotechnology · 2 employees
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Healthcare · Biotechnology · 11 employees
BBLG vs BDRX FAQ
Which is bigger, Bone Biologics or Biodexa Pharmaceuticals American Depositary Shs?
Bone Biologics (BBLG) is larger, with a market capitalization of $1.29M compared with $1.15M for Biodexa Pharmaceuticals American Depositary Shs (BDRX).
Are Bone Biologics and Biodexa Pharmaceuticals American Depositary Shs in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.